Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will present at the 9th Annual Nordic-American Healthcare Conference (NAHC), a pre-eminent US-based Nordic healthcare equity investor event bringing together industry leaders, investors and innovators from across the global healthcare sector. Presented by the DNB//Back Bay Healthcare Partnership, in collaboration with Nasdaq Nordic, the event takes place in New York City on March 26-27, 2025. NAHC serves as a premier platform, uniting large and mid-cap public and private IPO-ready US and Nordic life science companies.
Sten R. Sörensen, CEO of Cereno Scientific will present on March 26, 2025, to investors, corporate development executives and industry partners. This event is for registered attendees only, but the presentation will be available on Cereno Scientific's website following the event.
"Following on from the positive experience at J.P. Morgan Healthcare Week, we are pleased to continue dialogues around our clinical-stage HDAC inhibitor portfolio, CS1 and CS014, with disease-modifying potential. We are excited to discuss the significant progress that has been made these last twelve months with our lead program CS1 that reported positive top-line data from a Phase IIa trial in PAH and, our novel HDACi CS014 that is progressing towards completion of Phase I in mid-2025," said Sten R. Sörensen, CEO of Cereno Scientific. "The positive signals we get when we are out talking about our company and portfolio indicates that there is a keen market interest for a pioneering treatment approach to rare cardiovascular and pulmonary diseases."
Over the course of two days at NAHC 2025, healthcare companies and investors will come together to cultivate networks, foster innovation, and develop the next generation of medication, diagnostics, and healthcare tools. In addition to presentations by highly curated private and public healthcare companies, attendees will have the opportunity to participate in panel discussions focused on four specialized tracks in the areas of rare disease, biopharma advances, oncology, and medtech.
For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: tove.bergenholt@cerenoscientific.com
Phone: +46 73- 236 62 46
Sten R. Sörensen, CEO
Email: sten.sorensen@cerenoscientific.com
Phone: +46 73-374 03 74
About The Nordic-American Healthcare Conference
Now in its ninth year, the Nordic-American Healthcare Conference, is the largest US-Nordic life science forum in the United States with a mission to foster US-Nordic healthcare collaboration. Life sciences companies and investors from both regions join with partners, business development executives and an exceptional network of contributors from the private and public sectors to bring the most promising Nordic healthcare to the global market.
The NAHC is a collaboration between the DNB//Back Bay Healthcare Partnership and Nasdaq Nordic. Innovation Norway, A&O Shearman, Business Sweden, The Consulate General of Sweden in New York, and Medicon Valley Alliance are also valued contributors and supporters.
For more information, please visit https://nordicamericanhealthcareconference.com/ or contact the organizers via email at healthcarepartnership@bblsa.com.
About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.
The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.